ReviewFrontiers in immunology2026
Metabolic checkpoints in the regulation of Th17 cells: implications for uveitis pathogenesis and therapy.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The disruption of the balance between helper T cells (Th17) and regulatory T cells (Tregs) is associated with various autoimmune diseases. Th17 cells contribute to inflammation, whereas Tregs play a crucial role in suppressing autoimmunity. Th17 cells are central to the pathogenesis of autoimmune diseases, with specific metabolic pathways, enzymes, signaling pathways, and transcription factors acting as key checkpoints that influence T cell differentiation and immune responses. This review aims to summarize recent advances in understanding the role of Th17 cells and the Th17/Treg immune balance in the pathogenesis of uveitis, focusing on the impact of metabolic reprogramming on the activation, differentiation, and effector functions of T cells. Understanding the regulators of key metabolic checkpoints offers promising prospects for the treatment of autoimmune diseases, including Th17-mediated uveitis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.